VTE in Palliative Care Patients: What do we know? A talk report from the 10th ICTHC
During the 10th ICTHIC, Professor Simon Noble (Cardiff University, UK) talked about the management of VTE in patients...
Most Read
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological...
Lung Cancer CAT Patient Profiles
Over the past 3 or 4 years, we have witnessed a nearly doubled survival rate among patients with metastatic and...
The impact of warfarin on overall survival in cancer patients with VTE
During the 11th ICTHIC, 2022, Jeffrey Zwicker talked about the impact of warfarin on overall survival (OS) in cancer...
Use of tinzaparin in CAT patients with metastatic disease: a post hoc analysis of the CATCH trial
Introduction The management of cancer-associated thrombosis (CAT) is tricky because of the high risk of recurrent...
Can Thrombophilia Gene Mutations be Predictors of VTE in Ambulatory Cancer Patients Undergoing Chemotherapy?
Thrombophilia refers to a group of conditions where the blood has an elevated tendency to form clots. It can stem from...
Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...
The USCAT study: a retrospective non-interventional study to examine long-term treatment of CAT
Patients with cancer are at high risk of venous thromboembolism (VTE) recurrence and major bleeding (1). Most...
Flash Interviews from the 11th ICTHIC
Anna-Karin Olsson: What are the main take-home messages from “Neutrophil extracellular traps promote...